Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients

Samuel F. Gilbert, Amr S Soliman, Mehdi Karkouri, Meaghen Quinlan-Davidson, Ashley Strahley, Mohab Eissa, Subhojit Dey, Ahmed Hablas, Ibrahim A. Seifeldin, Mohamed Ramadan, Noureddine Benjaafar, Kathy Toy, Sofia D. Merajver

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Male breast cancer (MBC) is a rare disease. Rates of MBC in Northern Africa vary by region. The age-standardized incidence for MBC is higher in Morocco than in Egypt, and the Egyptian rate is similar to the U.S of approximately 1/105. This study aimed at investigating the clinical and molecular characteristics of MBC in Egypt and Morocco. Methods: This case-case study included 211 cases from Egypt and 132 from Morocco. Tumor tissues were available for 47 Egyptian and 18 Moroccan patients. Medical record information was abstracted for patients' demographics, medical history, and treatment. BRCA2 protein expression status was examined in Egyptian and Moroccan tumors. Androgen receptor CAG repeat length was analyzed using the tissue samples in Egyptian MBC tumors and controls. Limited amount of tissues from Morocco did not allow for the analysis of CAG repeats. Results: Egyptian MBC patients had a significantly lower age at diagnosis (Egypt: 57.5 ± 15.1, Morocco: 63.9 ± 14.4, P=0.0002) and a higher prevalence of liver cirrhosis (Egypt: 28.0%, Morocco: 0.8%, P=< 0.0001). MBC patients also had higher tumor grades [I (0.9%), II (81.0%), III (18.1%)] in Egypt vs. [I (10.7%), II (81.0%), III (8.3%)] in Morocco (P=0.0017). The clinical and molecular characteristics of the groups from the 2 countries did not significantly differ. There was no significant difference with respect to BRCA2 expression amongst countries (Egypt: 28.9% non-wild type, Morocco: 27.8% non-wild type, P=0.9297) or CAG lengths amongst BRCA2 expression types in Egyptians (Wild type: 54.6% with CAG repeat lengths of 20+, Non-wild type: 50% with CAG repeat lengths of 20+, P=0.7947). Conclusions: Differences in MBC between Egypt and Morocco are more likely due to differences in other risk factors such as consanguinity and use of xenoestrogenic pesticides.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalBreast Disease
Volume33
Issue number1
DOIs
StatePublished - Dec 1 2011

Fingerprint

Male Breast Neoplasms
Morocco
Androgen Receptors
Egypt
BRCA2 Protein
Consanguinity
Northern Africa
Neoplasms
Rare Diseases
Pesticides
Liver Cirrhosis
Medical Records
Demography

Keywords

  • Egypt
  • Male breast cancer
  • Morocco
  • breast cancer
  • developing countries

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gilbert, S. F., Soliman, A. S., Karkouri, M., Quinlan-Davidson, M., Strahley, A., Eissa, M., ... Merajver, S. D. (2011). Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. Breast Disease, 33(1), 17-26. https://doi.org/10.3233/BD-2010-0323

Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. / Gilbert, Samuel F.; Soliman, Amr S; Karkouri, Mehdi; Quinlan-Davidson, Meaghen; Strahley, Ashley; Eissa, Mohab; Dey, Subhojit; Hablas, Ahmed; Seifeldin, Ibrahim A.; Ramadan, Mohamed; Benjaafar, Noureddine; Toy, Kathy; Merajver, Sofia D.

In: Breast Disease, Vol. 33, No. 1, 01.12.2011, p. 17-26.

Research output: Contribution to journalArticle

Gilbert, SF, Soliman, AS, Karkouri, M, Quinlan-Davidson, M, Strahley, A, Eissa, M, Dey, S, Hablas, A, Seifeldin, IA, Ramadan, M, Benjaafar, N, Toy, K & Merajver, SD 2011, 'Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients', Breast Disease, vol. 33, no. 1, pp. 17-26. https://doi.org/10.3233/BD-2010-0323
Gilbert, Samuel F. ; Soliman, Amr S ; Karkouri, Mehdi ; Quinlan-Davidson, Meaghen ; Strahley, Ashley ; Eissa, Mohab ; Dey, Subhojit ; Hablas, Ahmed ; Seifeldin, Ibrahim A. ; Ramadan, Mohamed ; Benjaafar, Noureddine ; Toy, Kathy ; Merajver, Sofia D. / Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. In: Breast Disease. 2011 ; Vol. 33, No. 1. pp. 17-26.
@article{1af14b5c16174129bfe47b22fc78f5b1,
title = "Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients",
abstract = "Introduction: Male breast cancer (MBC) is a rare disease. Rates of MBC in Northern Africa vary by region. The age-standardized incidence for MBC is higher in Morocco than in Egypt, and the Egyptian rate is similar to the U.S of approximately 1/105. This study aimed at investigating the clinical and molecular characteristics of MBC in Egypt and Morocco. Methods: This case-case study included 211 cases from Egypt and 132 from Morocco. Tumor tissues were available for 47 Egyptian and 18 Moroccan patients. Medical record information was abstracted for patients' demographics, medical history, and treatment. BRCA2 protein expression status was examined in Egyptian and Moroccan tumors. Androgen receptor CAG repeat length was analyzed using the tissue samples in Egyptian MBC tumors and controls. Limited amount of tissues from Morocco did not allow for the analysis of CAG repeats. Results: Egyptian MBC patients had a significantly lower age at diagnosis (Egypt: 57.5 ± 15.1, Morocco: 63.9 ± 14.4, P=0.0002) and a higher prevalence of liver cirrhosis (Egypt: 28.0{\%}, Morocco: 0.8{\%}, P=< 0.0001). MBC patients also had higher tumor grades [I (0.9{\%}), II (81.0{\%}), III (18.1{\%})] in Egypt vs. [I (10.7{\%}), II (81.0{\%}), III (8.3{\%})] in Morocco (P=0.0017). The clinical and molecular characteristics of the groups from the 2 countries did not significantly differ. There was no significant difference with respect to BRCA2 expression amongst countries (Egypt: 28.9{\%} non-wild type, Morocco: 27.8{\%} non-wild type, P=0.9297) or CAG lengths amongst BRCA2 expression types in Egyptians (Wild type: 54.6{\%} with CAG repeat lengths of 20+, Non-wild type: 50{\%} with CAG repeat lengths of 20+, P=0.7947). Conclusions: Differences in MBC between Egypt and Morocco are more likely due to differences in other risk factors such as consanguinity and use of xenoestrogenic pesticides.",
keywords = "Egypt, Male breast cancer, Morocco, breast cancer, developing countries",
author = "Gilbert, {Samuel F.} and Soliman, {Amr S} and Mehdi Karkouri and Meaghen Quinlan-Davidson and Ashley Strahley and Mohab Eissa and Subhojit Dey and Ahmed Hablas and Seifeldin, {Ibrahim A.} and Mohamed Ramadan and Noureddine Benjaafar and Kathy Toy and Merajver, {Sofia D.}",
year = "2011",
month = "12",
day = "1",
doi = "10.3233/BD-2010-0323",
language = "English (US)",
volume = "33",
pages = "17--26",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients

AU - Gilbert, Samuel F.

AU - Soliman, Amr S

AU - Karkouri, Mehdi

AU - Quinlan-Davidson, Meaghen

AU - Strahley, Ashley

AU - Eissa, Mohab

AU - Dey, Subhojit

AU - Hablas, Ahmed

AU - Seifeldin, Ibrahim A.

AU - Ramadan, Mohamed

AU - Benjaafar, Noureddine

AU - Toy, Kathy

AU - Merajver, Sofia D.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Introduction: Male breast cancer (MBC) is a rare disease. Rates of MBC in Northern Africa vary by region. The age-standardized incidence for MBC is higher in Morocco than in Egypt, and the Egyptian rate is similar to the U.S of approximately 1/105. This study aimed at investigating the clinical and molecular characteristics of MBC in Egypt and Morocco. Methods: This case-case study included 211 cases from Egypt and 132 from Morocco. Tumor tissues were available for 47 Egyptian and 18 Moroccan patients. Medical record information was abstracted for patients' demographics, medical history, and treatment. BRCA2 protein expression status was examined in Egyptian and Moroccan tumors. Androgen receptor CAG repeat length was analyzed using the tissue samples in Egyptian MBC tumors and controls. Limited amount of tissues from Morocco did not allow for the analysis of CAG repeats. Results: Egyptian MBC patients had a significantly lower age at diagnosis (Egypt: 57.5 ± 15.1, Morocco: 63.9 ± 14.4, P=0.0002) and a higher prevalence of liver cirrhosis (Egypt: 28.0%, Morocco: 0.8%, P=< 0.0001). MBC patients also had higher tumor grades [I (0.9%), II (81.0%), III (18.1%)] in Egypt vs. [I (10.7%), II (81.0%), III (8.3%)] in Morocco (P=0.0017). The clinical and molecular characteristics of the groups from the 2 countries did not significantly differ. There was no significant difference with respect to BRCA2 expression amongst countries (Egypt: 28.9% non-wild type, Morocco: 27.8% non-wild type, P=0.9297) or CAG lengths amongst BRCA2 expression types in Egyptians (Wild type: 54.6% with CAG repeat lengths of 20+, Non-wild type: 50% with CAG repeat lengths of 20+, P=0.7947). Conclusions: Differences in MBC between Egypt and Morocco are more likely due to differences in other risk factors such as consanguinity and use of xenoestrogenic pesticides.

AB - Introduction: Male breast cancer (MBC) is a rare disease. Rates of MBC in Northern Africa vary by region. The age-standardized incidence for MBC is higher in Morocco than in Egypt, and the Egyptian rate is similar to the U.S of approximately 1/105. This study aimed at investigating the clinical and molecular characteristics of MBC in Egypt and Morocco. Methods: This case-case study included 211 cases from Egypt and 132 from Morocco. Tumor tissues were available for 47 Egyptian and 18 Moroccan patients. Medical record information was abstracted for patients' demographics, medical history, and treatment. BRCA2 protein expression status was examined in Egyptian and Moroccan tumors. Androgen receptor CAG repeat length was analyzed using the tissue samples in Egyptian MBC tumors and controls. Limited amount of tissues from Morocco did not allow for the analysis of CAG repeats. Results: Egyptian MBC patients had a significantly lower age at diagnosis (Egypt: 57.5 ± 15.1, Morocco: 63.9 ± 14.4, P=0.0002) and a higher prevalence of liver cirrhosis (Egypt: 28.0%, Morocco: 0.8%, P=< 0.0001). MBC patients also had higher tumor grades [I (0.9%), II (81.0%), III (18.1%)] in Egypt vs. [I (10.7%), II (81.0%), III (8.3%)] in Morocco (P=0.0017). The clinical and molecular characteristics of the groups from the 2 countries did not significantly differ. There was no significant difference with respect to BRCA2 expression amongst countries (Egypt: 28.9% non-wild type, Morocco: 27.8% non-wild type, P=0.9297) or CAG lengths amongst BRCA2 expression types in Egyptians (Wild type: 54.6% with CAG repeat lengths of 20+, Non-wild type: 50% with CAG repeat lengths of 20+, P=0.7947). Conclusions: Differences in MBC between Egypt and Morocco are more likely due to differences in other risk factors such as consanguinity and use of xenoestrogenic pesticides.

KW - Egypt

KW - Male breast cancer

KW - Morocco

KW - breast cancer

KW - developing countries

UR - http://www.scopus.com/inward/record.url?scp=84858246379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858246379&partnerID=8YFLogxK

U2 - 10.3233/BD-2010-0323

DO - 10.3233/BD-2010-0323

M3 - Article

VL - 33

SP - 17

EP - 26

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

IS - 1

ER -